While international markets have more volatility and lower trust, their biggest advantage is inefficiency. Many basic services are underdeveloped, creating enormous 'low-hanging fruit' opportunities. Providing a great, reliable service in a market where few things work well can create immense and durable value.

A European founder targeting the US market shouldn't dismiss European VCs. You might be the top priority in a European firm's portfolio, receiving more attention and support than you would as a lower-priority deal for a top-tier, oversubscribed Silicon Valley firm.

The owner of Canada's only real estate trade publication is delaying U.S. expansion. He's choosing to solidify his monopoly and become the 'big fish' in his home market rather than becoming a 'little fish' in the crowded U.S. market where his brand has no equity and he'd face established competitors.

CEO Keller Rinaudo Cliffton explains that developing nations can be superior markets for launching disruptive tech. Rwanda's regulatory agility and hunger to adopt new paradigms allowed Zipline to deploy and prove its technology faster than would have been possible in the U.S.

For global expansion, view countries as having unique attributes like players on a sports team. Outsized returns come from matching your business to a country's inherent 'raw material' strengths—such as leveraging the US for its market liquidity, or Australia for its abundant land and sun for solar projects.

Instead of concentrating its sales force in one region, Deel hired individual salespeople in various countries early in its journey. This counterintuitive move, often criticized as defocusing, allowed the company to quickly test and understand multiple markets in parallel. This strategy was key to rapidly ramping up a global go-to-market motion with localized insights.

The allure of expanding into a major market like New York City can be a trap. Fully exploit the potential of your existing, more manageable markets first. Chasing expansion for the sake of prestige before you've maximized local potential is a common business mistake.

The CEO of Korean startup Apollon, who moved his family to Cambridge, argues that sending a representative is insufficient for US expansion. He advises that the CEO must be physically present "on the ground" to build trust, navigate the ecosystem, and demonstrate commitment—a crucial lesson for any international startup targeting the US.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.